NeoCannBio is based in Seoul, South Korea. It has raised $11M in total funding. Latest round: Series B.
NeoCannBio funding overview
NeoCannBio is based in Seoul, South Korea. NeoCannBio has raised $11M in total disclosed funding. That places its disclosed total in the $1M–$25M range. Its most recent disclosed round is a Series B announced in September 2023. The round record for NeoCannBio runs through 2023; nothing later has been disclosed. Investors on record include Quad Investment Management, Bilanx Investment, Donghun Investment, Prologue Ventures, Meditox Ventures, HLB Investment and 2 others. 8 distinct backers are named across the disclosed rounds.
NeoCannBio at a glance
Total raised
$11M
Latest round
Series B
Latest round date
September 2023
Headquarters
Seoul, South Korea
Notable investors
Quad Investment Management, Bilanx Investment, Donghun Investment, Prologue Ventures, Meditox Ventures, HLB Investment, BM Ventures, Korea Institute of Science and Technology (KIST)
Frequently asked about NeoCannBio funding
How much has NeoCannBio raised?
NeoCannBio has raised $11M in total disclosed funding across the rounds on record.
Who has invested in NeoCannBio?
Quad Investment Management, Bilanx Investment, Donghun Investment, Prologue Ventures, Meditox Ventures, HLB Investment are named among the investors backing NeoCannBio.
What was the latest NeoCannBio funding round?
The most recent disclosed round is a Series B, announced in September 2023.
Where is NeoCannBio based?
NeoCannBio is based in Seoul, South Korea.
When did NeoCannBio last raise?
The last disclosed NeoCannBio round closed in September 2023 at Series B.
Totals shown for NeoCannBio aggregate every disclosed round on file. To see how that compares, browse the companies in Seoul and the investors behind them below.
